Shayna Sarosiek, MD | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Loncastuximab Tesirine in WM	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2026-05-20		NCT05190705
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia	B-cell neoplasm, Blood Protein Disorders, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 2	2025-12-05		NCT06986174
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, nervous system disorder, neuritis, neuromuscular disease, peripheral nervous system disorder, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2025-12-05		NCT05065554